A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa
A study for patients with Epidermolysis Bullosa using study cream, Zorblisa (SD-101)
Sponsor: Scioderm Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ8842
U.S. Govt. ID: NCT02384460
Contact: Kimberly Morel: 212-305-5293 / km208@columbia.edu
Additional Study Information: This clinical study is being conducted for research purposes. The study cream, SD-101 (Zorblisa), has allantoin as the active ingredient and is being investigated for the treatment of the skin lesions which occur in patients with Epidermolysis Bullosa. The purpose of this clinical study is to study the effectiveness and safety of SD-101 (Zorblisa) in treating these skin lesions.
This study is closed
Investigator
Kimberly Morel, MD
Do You Qualify?
Have you been diagnosed with Epidermolysis Bullosa? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kimberly Morel
km208@columbia.edu
212-305-5293
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE